Barriers and strategies to enhance HPV vaccine uptake in adolescents living with HIV and their guardians in Lilongwe, Malawi.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Papillomavirus Vaccines*/administration & dosage ; HIV Infections*/epidemiology ; HIV Infections*/complications ; HIV Infections*/virology ; Papillomavirus Infections*/prevention & control ; Papillomavirus Infections*/epidemiology ; Uterine Cervical Neoplasms*/prevention & control ; Uterine Cervical Neoplasms*/virology ; Patient Acceptance of Health Care*; Humans ; Female ; Adolescent ; Malawi/epidemiology ; Vaccination ; Health Knowledge, Attitudes, Practice ; Focus Groups ; Adult ; Young Adult

Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Ethical clearance: The study was approved by the College of Medicine Research and Ethics Committee (COMREC P.11/21/3451). Permission was granted by the Lilongwe District Health Office. Informed Consent was obtained from all the participants. All minors involved in the study had their parents or guardians provide parental consent. In addition, written assent was obtained from each minor. All participants were assured of their privacy, confidentiality, and anonymity, and discussions were conducted in private settings to provide a safe environment for participants to share their experiences without fear of disclosure.
Female Adolescents Infected with HIV are at higher risk for Human Papillomavirus -related cancers later in life, making them a priority for HPV vaccination. Since HPV-related cancers typically develop after adolescence, HPV vaccination before exposure to HPV infection is most effective. Increasing vaccination rates in this group is key to reducing the risk of cervical cancer incidence. The Global Action strategy to eliminate cervical cancer requires achieving 90% national coverage and 80% district coverage for HPV vaccination. However, the uptake of HPV vaccine in Malawi has been slow, with an uptake of less than 73%. This study explored the barriers of HPV vaccine uptake and identified strategies to improve vaccination rates among female adolescents infected with HIV in Lilongwe, Malawi. This qualitative phenomenological study employed two focus group discussions and 12 in-depth interviews with female Adolescents infected with HIV, healthcare workers and caregivers respectively. Study participants were sampled from Mitundu Community Hospital and Area 18 Urban Health Centre in April 2022. Female Adolescents infected with HIV were sampled through teen clubs. Thirty participants were enrolled using quota sampling. Recorded interviews were transcribed verbatim and translated into English for analysis. The data were analysed using a thematic approach. The barriers to the uptake of the HPV vaccine were negative attitudes towards the HPV vaccine and misconceptions about the vaccine due to inadequate or incorrect HPV vaccine information, lack of adequate HPV vaccine information, and shortage of HPV vaccine. Strategies for improving the uptake of HPV vaccines include raising awareness and sensitization about HPV, resource availability, and advocating for other HPV vaccine delivery modes, such as the integration of HPV-related interventions in teen clubs to enhance vaccine uptake. Overall, teen club clinic days were proposed as the best days to identify unvaccinated female adolescents and recommend the HPV vaccine. Teen clubs should be well positioned to fill the gap in previously lost opportunities for vaccine administration and empower female adolescents infected with HIV by endorsing the HPV vaccine. Further research should explore the feasibility and readiness of administering the HPV vaccination in teen club clinics.
(© 2025. The Author(s).)

Healthcare (Basel). 2017 Nov 06;5(4):. (PMID: 29113137)
Front Public Health. 2024 Jan 17;12:1343064. (PMID: 38299075)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
PLoS One. 2012;7(10):e45231. (PMID: 23115621)
Public Health Nurs. 2013 Sep-Oct;30(5):451-3. (PMID: 24000918)
J Obstet Gynaecol. 2020 Jul;40(5):602-608. (PMID: 31500479)
Women Health. 2013;53(6):630-45. (PMID: 23937733)
Vaccines (Basel). 2022 Sep 12;10(9):. (PMID: 36146593)
Front Public Health. 2015 Nov 26;3:269. (PMID: 26636066)
Vaccines (Basel). 2023 Oct 19;11(10):. (PMID: 37897016)
Ann Glob Health. 2020 Sep 17;86(1):118. (PMID: 32983914)
BMC Public Health. 2023 Feb 6;23(1):255. (PMID: 36747179)
Soc Sci Med. 2023 Mar;320:115695. (PMID: 36736053)
Vaccine. 2022 Mar 31;40 Suppl 1:A26-A29. (PMID: 33509696)
Microorganisms. 2022 May 18;10(5):. (PMID: 35630489)
Hum Vaccin Immunother. 2019;15(4):1005-1012. (PMID: 30230946)
Elife. 2023 Aug 18;12:. (PMID: 37594016)
Int J Gynaecol Obstet. 2021 Jan;152(1):32-39. (PMID: 33185283)
J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S367-S378. (PMID: 34590141)
J Cancer Educ. 2018 Apr;33(2):332-339. (PMID: 27640203)
Vaccine. 2016 Feb 24;34(9):1187-92. (PMID: 26812078)
Front Public Health. 2023 Apr 14;11:1112981. (PMID: 37124764)
Health Educ Q. 1988 Winter;15(4):351-77. (PMID: 3068205)
JAMA Netw Open. 2021 Aug 2;4(8):e2120391. (PMID: 34436612)
Vaccine. 2018 Jan 4;36(2):191-193. (PMID: 29198915)
Hum Vaccin Immunother. 2023 Dec 31;19(1):2181610. (PMID: 36882951)
Prev Med. 2021 Mar;144:106335. (PMID: 33678232)
Hum Vaccin Immunother. 2019;15(7-8):1544-1548. (PMID: 31063078)
Int J Cancer. 2017 Aug 15;141(4):664-670. (PMID: 28369882)
Vaccine. 2023 Jun 1;41(24):3647-3654. (PMID: 37173265)
Front Med (Lausanne). 2021 Aug 17;8:700792. (PMID: 34485336)
Hum Vaccin Immunother. 2023 Dec 31;19(1):2214054. (PMID: 37212294)
Papillomavirus Res. 2020 Jun;9:100195. (PMID: 32205196)
Reprod Health. 2021 Apr 1;18(1):72. (PMID: 33794938)
Vaccine. 2020 May 19;38(24):4038-4043. (PMID: 32253100)
Papillomavirus Res. 2019 Dec;8:100170. (PMID: 31176807)
Vaccines (Basel). 2021 Sep 28;9(10):. (PMID: 34696206)
Vaccine X. 2023 May 16;14:100315. (PMID: 37251590)
BMC Public Health. 2017 Jun 26;17(1):599. (PMID: 28651574)
PEC Innov. 2024 Mar 12;4:100272. (PMID: 38525313)

Keywords: Barriers; Female adolescents infected with HIV; Human papillomavirus (HPV) vaccine; Malawi

0 (Papillomavirus Vaccines)

Date Created: 20250901 Date Completed: 20250901 Latest Revision: 20250904

20250904

PMC12402499

10.1038/s41598-025-03145-x

40890168